Ofatumumab

Grey

Brand Name(s):Arzerra

Indication:Chronic lymphocytic leukaemia

Rationale:1

Considered:Jan-09

Review Date:Jun-20

Comments:
NICE TA344
Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Full guidance available at:http://www.nice.org.uk/guidance/ta344/resources/guidance-ofatumumab-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia-pdf
June 2015
…………………………
MHRA Drug Safety Update
Screen all pts for Hep B virus before treatment, further information at http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON364166
January 2014

…………………………

1.1 Ofatumumab is not recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.

1.2 People currently receiving ofatumumab for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab should have the option to continue treatment until they and their clinician consider it appropriate to stop.

NICE TA202
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab October 2010